×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
SNOA – sonoma pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
SNOA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/5
08:51 am
snoa
Sonoma Pharmaceuticals Successfully Transitions First Products to New EU MDR Requirements for Class IIb Medical Devices [Yahoo! Finance]
Medium
Report
Sonoma Pharmaceuticals Successfully Transitions First Products to New EU MDR Requirements for Class IIb Medical Devices [Yahoo! Finance]
12/5
08:30 am
snoa
Sonoma Pharmaceuticals Successfully Transitions First Products to New EU MDR Requirements for Class IIb Medical Devices
Medium
Report
Sonoma Pharmaceuticals Successfully Transitions First Products to New EU MDR Requirements for Class IIb Medical Devices
11/21
04:11 pm
snoa
Sonoma Pharmaceuticals Announces Relaunch of Prescription Dermatology and Eye Care Product Lines in the United States [Yahoo! Finance]
Medium
Report
Sonoma Pharmaceuticals Announces Relaunch of Prescription Dermatology and Eye Care Product Lines in the United States [Yahoo! Finance]
11/21
04:06 pm
snoa
Sonoma Pharmaceuticals Announces Relaunch of Prescription Dermatology and Eye Care Product Lines in the United States
Medium
Report
Sonoma Pharmaceuticals Announces Relaunch of Prescription Dermatology and Eye Care Product Lines in the United States
11/11
04:20 pm
snoa
Sonoma Pharmaceuticals Receives New FDA 510(k) Clearance for Microcyn(R)-based Wound Care Hydrogel
High
Report
Sonoma Pharmaceuticals Receives New FDA 510(k) Clearance for Microcyn(R)-based Wound Care Hydrogel
11/9
08:42 am
snoa
Sonoma Pharmaceuticals Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]
High
Report
Sonoma Pharmaceuticals Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]
11/7
08:45 am
snoa
Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2025 Financial Results
High
Report
Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2025 Financial Results
10/31
04:01 pm
snoa
Sonoma Pharmaceuticals to Exhibit at MEDICA 2024 in Düsseldorf
Medium
Report
Sonoma Pharmaceuticals to Exhibit at MEDICA 2024 in Düsseldorf
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/3
05:02 pm
snoa
Form 4 Sonoma Pharmaceuticals, For: Jan 02 Filed by: Thornton Bruce
Low
Report
Form 4 Sonoma Pharmaceuticals, For: Jan 02 Filed by: Thornton Bruce
1/3
05:02 pm
snoa
Form 4 Sonoma Pharmaceuticals, For: Jan 02 Filed by: Trombly Amy Moss
Low
Report
Form 4 Sonoma Pharmaceuticals, For: Jan 02 Filed by: Trombly Amy Moss
1/3
05:02 pm
snoa
Form 4 Sonoma Pharmaceuticals, For: Jan 02 Filed by: Weigerstorfer Philippe
Low
Report
Form 4 Sonoma Pharmaceuticals, For: Jan 02 Filed by: Weigerstorfer Philippe
1/3
05:02 pm
snoa
Form 4 Sonoma Pharmaceuticals, For: Jan 02 Filed by: Birnbaum Jay E
Low
Report
Form 4 Sonoma Pharmaceuticals, For: Jan 02 Filed by: Birnbaum Jay E
1/3
05:02 pm
snoa
Form 4 Sonoma Pharmaceuticals, For: Jan 02 Filed by: Dal Poggetto John
Low
Report
Form 4 Sonoma Pharmaceuticals, For: Jan 02 Filed by: Dal Poggetto John
1/3
05:02 pm
snoa
Form 4 Sonoma Pharmaceuticals, For: Jan 02 Filed by: DVONCH JEROME J
Low
Report
Form 4 Sonoma Pharmaceuticals, For: Jan 02 Filed by: DVONCH JEROME J
1/3
05:02 pm
snoa
Form 4 Sonoma Pharmaceuticals, For: Jan 02 Filed by: MCLAUGHLIN JOHN
Low
Report
Form 4 Sonoma Pharmaceuticals, For: Jan 02 Filed by: MCLAUGHLIN JOHN
1/3
05:01 pm
snoa
Form 8-K Sonoma Pharmaceuticals, For: Jan 02
Low
Report
Form 8-K Sonoma Pharmaceuticals, For: Jan 02
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
11/26
Sonoma Pharmaceuticals Announces Pricing of Approximately $1.6 million Public Offering of Common Stock
13.9%
11/14 Q2/2020 9/30/2019 EPS -0.910 ZacksConsensus N/A ActVsEst N/A - N/A 10.8%
1/23 Sonoma Pharmaceuticals Engages Maxim Group LLC to Explore Strategic Opportunities for its U.S. Dermatology Division 9.8%
2/14 Q3/2020 12/31/2019 EPS -0.720 ZacksConsensus N/A ActVsEst N/A - N/A 9.8%
4/24 Form 4 Sonoma Pharmaceuticals, For: Apr 23 Filed by: Dal Poggetto John 7.3%
10/3 Form DEFA14A Sonoma Pharmaceuticals, 5.7%
12/31 Form 8-K Sonoma Pharmaceuticals, For: Dec 26 4.4%
7/29 Form DEF 14A Sonoma Pharmaceuticals, For: Sep 17 4.3%
5/22 Form 8-K Sonoma Pharmaceuticals, For: May 20 2.9%
5/31 Form 8-K Sonoma Pharmaceuticals, For: May 30 2.2%
11/14 Q2/2020 9/30/2019 EPS -0.910 ZacksConsensus N/A ActVsEst N/A - N/A 10.8%
1/23 Sonoma Pharmaceuticals Engages Maxim Group LLC to Explore Strategic Opportunities for its U.S. Dermatology Division 9.8%
2/14 Q3/2020 12/31/2019 EPS -0.720 ZacksConsensus N/A ActVsEst N/A - N/A 9.8%
4/24 Form 4 Sonoma Pharmaceuticals, For: Apr 23 Filed by: Dal Poggetto John 7.3%
10/3 Form DEFA14A Sonoma Pharmaceuticals, 5.7%
12/31 Form 8-K Sonoma Pharmaceuticals, For: Dec 26 4.4%
7/29 Form DEF 14A Sonoma Pharmaceuticals, For: Sep 17 4.3%
5/22 Form 8-K Sonoma Pharmaceuticals, For: May 20 2.9%
5/31 Form 8-K Sonoma Pharmaceuticals, For: May 30 2.2%
TOP News Decliners
10/1
Sonoma Pharmaceuticals Announces Management Changes
-11.3%
8/13 Sonoma Pharmaceuticals Reports First Quarter FY 2020 Financial Results -7.1%
7/8 Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2019 Financial Results -5.1%
12/26 Form S-8 Sonoma Pharmaceuticals, -4.5%
7/12 Sonoma Pharmaceuticals Regains Compliance with Nasdaq® Minimum Bid Price Rule -4.2%
4/20 Form 8-K Sonoma Pharmaceuticals, For: Apr 14 -3.9%
11/27 Form 424B3 Sonoma Pharmaceuticals, -3.8%
6/12 Form 8-K Sonoma Pharmaceuticals, For: Jun 11 -1.4%
11/25 Sonoma Pharmaceuticals Announces Proposed Public Offering of Common Stock -1.1%
5/21 Sonoma Pharmaceuticals Sells Animal Health Rights in Asia and Europe for $2.7 million -0.8%
8/13 Sonoma Pharmaceuticals Reports First Quarter FY 2020 Financial Results -7.1%
7/8 Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2019 Financial Results -5.1%
12/26 Form S-8 Sonoma Pharmaceuticals, -4.5%
7/12 Sonoma Pharmaceuticals Regains Compliance with Nasdaq® Minimum Bid Price Rule -4.2%
4/20 Form 8-K Sonoma Pharmaceuticals, For: Apr 14 -3.9%
11/27 Form 424B3 Sonoma Pharmaceuticals, -3.8%
6/12 Form 8-K Sonoma Pharmaceuticals, For: Jun 11 -1.4%
11/25 Sonoma Pharmaceuticals Announces Proposed Public Offering of Common Stock -1.1%
5/21 Sonoma Pharmaceuticals Sells Animal Health Rights in Asia and Europe for $2.7 million -0.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: